A study that surprised oncologists at the University of Iowa conducted a randomized phase 2 clinical trial on 34 patients with metastatic pancreatic cancer in 2024. The fourth stage, people who have months, not years, to live, have survived an average of 16 months with the addition of high doses of intravenous vitamin C to chemotherapy. Those with chemotherapy alone have survived eight months.
The time without disease progression was extended from four to six months. The study was published in November 2024 in the journal Redox Biology and was prematurely concluded because the results were so encouraging. The mechanism?
High doses of intravenous vitamin C act as a prooxidant, triggering the formation of hydrogen peroxide, which is selectively toxic to cancer cells, while healthy cells are mostly left alone. It’s almost like targeted chemotherapy.
Topics: #months #study #vitamin
